How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? by Nicholas J. Short, Farhad Ravandi

Get full text

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors by Nicholas J. Short, Daniel Nguyen, Farhad Ravandi

Get full text

Evaluation and management of measurable residual disease in acute lymphoblastic leukemia by Iman Abou Dalle, Elias Jabbour, Nicholas J. Short

Get full text

Treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens by Fadi G. Haddad, Jacki Sawyers, Nicholas J. Short

Get full text

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia by Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Naval Daver

Get full text

Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions by Nicholas J. Short, Elias Jabbour, Nitin Jain, Hagop Kantarjian

Get full text

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions by Bachar Samra, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Nicholas J. Short

Get full text

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia by Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short

Get full text

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia by Veronica A. Guerra, Elias J. Jabbour, Farhad Ravandi, Hagop Kantarjian, Nicholas J. Short

Get full text

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades by Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Mary Alma Welch, Farhad Ravandi, Hagop Kantarjian

Get full text

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia by Aram Bidikian, Hagop Kantarjian, Elias Jabbour, Nicholas J. Short, Keyur Patel, Farhad Ravandi, Koji Sasaki, Ghayas C. Issa

Get full text

Current status and research directions in acute myeloid leukemia by Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Ghayas Issa, Elias Jabbour, Tapan Kadia, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Farhad Ravandi

Get full text

Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia by Iman Abou Dalle, Ronald Paranal, Jabra Zarka, Shilpa Paul, Koji Sasaki, Wen Li, Jing Ning, Nicholas J. Short, Maro Ohanian, Jorge E. Cortes, Elias J. Jabbour, Ghayas C. Issa

Get full text

Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia by Amber Gibson, Cesar Nunez, Lindsay Robusto, Brianna Kammerer, Miriam Garcia, Michael Roth, Rachna Sheth, Priti Tewari, Aline Hittle, Laurie Toepfer, Romeo Torres, Nicholas J. Short, Elias Jabbour, Nitin Jain, Branko Cuglievan, David McCall

Get full text

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series by Ahmad S. Alotaibi, Musa Yilmaz, Sanam Loghavi, Courtney DiNardo, Gautam Borthakur, Tapan M. Kadia, Beenu Thakral, Naveen Pemmaraju, Ghayas C. Issa, Marina Konopleva, Nicholas J. Short, Keyur Patel, Guilin Tang, Farhad Ravandi, Naval Daver

Get full text

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozo... by Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi Haddad, Tharakeswara Bathala, Iuliia Kovalenko, Aram Bidikian, Farhad Ravandi, Issa Khouri, Tapan M. Kadia, Rebecca Garris, Guillermo Montalban Bravo, Kelly Chien, Elizabeth Shpall, Partow Kebriaei, Hagop M. Kantarjian

Get full text

Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis by Samuel Urrutia, Hagop M. Kantarjian, Farhad Ravandi-Kashani, Carlos Bueso-Ramos, Rashmi Kanagal-Shamanna, Elias Jabbour, Guillermo Montalban-Bravo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Courtney D. Dinardo, Tapan M. Kadia, Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Guillermo Garcia-Manero, Koji Sasaki

Get full text

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy by Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Get full text

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia by Hagop Kantarjian, Fadi G. Haddad, Nitin Jain, Koji Sasaki, Nicholas J. Short, Sanam Loghavi, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa Khouri, Partow Kebriaei, Yesid Alvarado, Tapan Kadia, Shilpa Paul, Guillermo Garcia-Manero, Bouthaina Dabaja, Musa Yilmaz, Jovitta Jacob, Rebecca Garris, Susan O’Brien, Farhad Ravandi, Elias Jabbour

Get full text

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements by Ghayas C. Issa, Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning, Nicholas J. Short, Fadi Haddad, Zhenya Tang, Keyur P. Patel, Branko Cuglievan, Naval Daver, Courtney D. DiNardo, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Hagop M. Kantarjian, Farhad Ravandi

Get full text